Tamara Hafner
Biographic Data
| ID | 6333511 |
|---|---|
| NAME | Tamara Hafner |
| GIVEN NAMES | Tamara |
| FAMILY NAME | Hafner |
| SIGNATURE | HAFNER T |
| AFFILIATIONS | Management Sciences for Health |
| ORCID | 0000-0002-4710-0979 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 32 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2013 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
Quality of adverse drug reaction reports submitted to the national pharmacovigilance center of Nepal
BACKGROUND: Pharmacovigilance (PV) plays a critical role in monitoring and evaluating adverse drug reactions (ADRs) to ensure the safety of marketed medical products. This study aimed to assess the quality of ADR reports submitted to the national PV center of Nepal by comparing pre- and post-training periods, and to identify factors associated with ADR reporting quality. METHODS: A retrospective analysis of ADR reports submitted to the national P…
Covid-19 vaccines pricing policy options for low-income and middle- income countries
box Affordable and equitable access to medical products and technologies have long been a challenge for health systems.1 The COVID-19 pandemic has further highlighted this critical challenge, making it a priority agenda issue for countries globally. Prices drive health expenditure and ultimately population-wide coverage and access to novel products. For example, DIME, an Inter-American Development Bank-funded project, estimated that Costa Rica, E…
The WHO Global Benchmarking Tool
Many low-income and middle-income countries lack the capacity to effectively and efficiently regulate medical products in their countries. To support countries in strengthening their capacity, WHO has developed the Global Benchmarking Tool (GBT) as the global standard for objectively assessing regulatory capacity for medicines and vaccines. The GBT is a game changer because it is the first globally accepted tool for assessing and strengthening na…
Defining pharmaceutical systems strengthening
Pharmaceutical products are indispensable for improving health outcomes. An extensive body of work on access to and use of medicines has resulted in an assortment of tools measuring various elements of pharmaceutical systems. Until now however, there has been little attempt to conceptualize a pharmaceutical system as an entity and define its strengthening in a way that allows for measuring systems strengthening. The narrow focus of available tool…
The emergence of global attention to health systems strengthening
After a period of proliferation of disease-specific initiatives, over the past decade and especially since 2005 many organizations involved in global health have come to direct attention and resources to the issue of health systems strengthening. We explore how and why such attention emerged. A qualitative methodology, process-tracing, was used to construct a case history and analyse the factors shaping and inhibiting global political attention f…
The emergence of global attention to health systems strengthening
After a period of proliferation of disease-specific initiatives, over the past decade and especially since 2005 many organizations involved in global health have come to direct attention and resources to the issue of health systems strengthening. We explore how and why such attention emerged. A qualitative methodology, process-tracing, was used to construct a case history and analyse the factors shaping and inhibiting global political attention f…
The emergence of global attention to health systems strengthening
After a period of proliferation of disease-specific initiatives, over the past decade and especially since 2005 many organizations involved in global health have come to direct attention and resources to the issue of health systems strengthening. We explore how and why such attention emerged. A qualitative methodology, process-tracing, was used to construct a case history and analyse the factors shaping and inhibiting global political attention f…
Defining pharmaceutical systems strengthening
Pharmaceutical products are indispensable for improving health outcomes. An extensive body of work on access to and use of medicines has resulted in an assortment of tools measuring various elements of pharmaceutical systems. Until now however, there has been little attempt to conceptualize a pharmaceutical system as an entity and define its strengthening in a way that allows for measuring systems strengthening. The narrow focus of available tool…
The WHO Global Benchmarking Tool
Many low-income and middle-income countries lack the capacity to effectively and efficiently regulate medical products in their countries. To support countries in strengthening their capacity, WHO has developed the Global Benchmarking Tool (GBT) as the global standard for objectively assessing regulatory capacity for medicines and vaccines. The GBT is a game changer because it is the first globally accepted tool for assessing and strengthening na…
Covid-19 vaccines pricing policy options for low-income and middle- income countries
box Affordable and equitable access to medical products and technologies have long been a challenge for health systems.1 The COVID-19 pandemic has further highlighted this critical challenge, making it a priority agenda issue for countries globally. Prices drive health expenditure and ultimately population-wide coverage and access to novel products. For example, DIME, an Inter-American Development Bank-funded project, estimated that Costa Rica, E…
Quality of adverse drug reaction reports submitted to the national pharmacovigilance center of Nepal
BACKGROUND: Pharmacovigilance (PV) plays a critical role in monitoring and evaluating adverse drug reactions (ADRs) to ensure the safety of marketed medical products. This study aimed to assess the quality of ADR reports submitted to the national PV center of Nepal by comparing pre- and post-training periods, and to identify factors associated with ADR reporting quality. METHODS: A retrospective analysis of ADR reports submitted to the national P…
Business (3 works) · Economic growth (3 works) · Economics (3 works) · Pharmaceutical Economics and Policy (3 works) · Computer Science (2 works) · Developing country (2 works) · Development economics (2 works) · Global Maternal and Child Health (2 works) · Health care (2 works) · Healthcare Systems and Reforms (2 works)